Multiple sclerosis progression: time for a new mechanism-driven framework

T Kuhlmann, M Moccia, T Coetzee, JA Cohen… - The Lancet …, 2023 - thelancet.com
Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—
relapsing-remitting, secondary progressive, and primary progressive—for patient care …

Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting

M Charabati, MA Wheeler, HL Weiner, FJ Quintana - Cell, 2023 - cell.com
Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central
nervous system afflicting nearly three million individuals worldwide. Neuroimmune …

Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination

M Zirngibl, P Assinck, A Sizov, AV Caprariello… - Molecular …, 2022 - Springer
Background The dietary consumption of cuprizone–a copper chelator–has long been known
to induce demyelination of specific brain structures and is widely used as model of multiple …

[HTML][HTML] Myelin in the central nervous system: structure, function, and pathology

C Stadelmann, S Timmler… - Physiological …, 2019 - journals.physiology.org
Oligodendrocytes generate multiple layers of myelin membrane around axons of the central
nervous system to enable fast and efficient nerve conduction. Until recently, saltatory nerve …

Pathogenic mechanisms associated with different clinical courses of multiple sclerosis

H Lassmann - Frontiers in immunology, 2019 - frontiersin.org
In the majority of patients multiple sclerosis starts with a relapsing remitting course (RRMS),
which may at later times transform into secondary progressive disease (SPMS). In a minority …

Multiple sclerosis: mechanisms and immunotherapy

C Baecher-Allan, BJ Kaskow, HL Weiner - Neuron, 2018 - cell.com
Multiple sclerosis (MS) is an autoimmune disease triggered by environmental factors that act
on a genetically susceptible host. It features three clinical stages: a pre-clinical stage …

The role of glial cells in multiple sclerosis disease progression

LM Healy, JA Stratton, T Kuhlmann… - Nature Reviews Neurology, 2022 - nature.com
Despite the development of highly effective treatments for relapsing–remitting multiple
sclerosis (MS), limited progress has been made in addressing primary progressive or …

Progressive multiple sclerosis: from pathophysiology to therapeutic strategies

S Faissner, JR Plemel, R Gold, VW Yong - Nature reviews drug …, 2019 - nature.com
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that
involves demyelination and axonal degeneration. Although substantial progress has been …

Multiple sclerosis pathology

H Lassmann - Cold Spring Harbor perspectives …, 2018 - perspectivesinmedicine.cshlp.org
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central
nervous system (CNS), which gives rise to focal lesions in the gray and white matter and to …

Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations

N Müller - Schizophrenia bulletin, 2018 - academic.oup.com
This paper discusses the current evidence from animal and human studies for a central role
of inflammation in schizophrenia. In animal models, pre-or perinatal elicitation of the immune …